News | December 19, 2025
JHS Svendgaard to invest Rs. 25 crore on building new manufacturing unit
The new facility is expected to generate 500-600 new jobs in the region
The new facility is expected to generate 500-600 new jobs in the region
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The center will deliver Certified Pre-Owned instruments restored to factory-grade standards and backed by Agilent Standard Warranty
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
The move strengthens GBL’s clinical-stage presence in the United States
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
Subscribe To Our Newsletter & Stay Updated
